BR0113854A - Polipeptìdeo do fator vii, construção de ácido nucleìco, célula hospedeira recombinante animal transgênico, planta transgênica, método para produzir o polipeptìdeo do fator vii, composição farmacêutica, uso de um polipeptìdeo do fator vii, e, métodos para o tratamento de episódios de sangramento e para tratamento ou profilaxia de distúrbios de sangramento em um indivìduo ou para a intensificação do sistema hemostático normal - Google Patents

Polipeptìdeo do fator vii, construção de ácido nucleìco, célula hospedeira recombinante animal transgênico, planta transgênica, método para produzir o polipeptìdeo do fator vii, composição farmacêutica, uso de um polipeptìdeo do fator vii, e, métodos para o tratamento de episódios de sangramento e para tratamento ou profilaxia de distúrbios de sangramento em um indivìduo ou para a intensificação do sistema hemostático normal

Info

Publication number
BR0113854A
BR0113854A BR0113854-5A BR0113854A BR0113854A BR 0113854 A BR0113854 A BR 0113854A BR 0113854 A BR0113854 A BR 0113854A BR 0113854 A BR0113854 A BR 0113854A
Authority
BR
Brazil
Prior art keywords
factor vii
vii polypeptide
nucleic acid
treatment
prophylaxis
Prior art date
Application number
BR0113854-5A
Other languages
English (en)
Inventor
Egon Persson
Ole Hvilsted Olsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Priority claimed from PCT/DK2001/000596 external-priority patent/WO2002022776A2/en
Publication of BR0113854A publication Critical patent/BR0113854A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"POLIPEPTìDEO DO FATOR VII, CONSTRUçãO DE áCIDO NUCLéICO, CéLULA HOSPEDEIRA RECOMBINANTE, ANIMAL TRANSGêNICO, PLANTA TRANSGêNICA, MéTODO PARA PRODUZIR O POLIPEPTìDEO DO FATOR VII, COMPOSIçãO FARMACêUTICA, USO DE UM POLIPEPTìDEO DO FATOR VII, E, MéTODOS PARA O TRATAMENTO DE EPISóDIOS DE SANGRAMENTO E PARA TRATAMENTO OU PROFILAXIA DE DISTúRBIOS DE SANGRAMENTO EM UM INDIVìDUO OU PARA A INTENSIFICAçãO DO SISTEMA HEMOSTáTICO NORMAL". A presente invenção diz respeito a novas variantes do Fator VIIa de coagulação humano tendo atividade coagulante, assim como a construções de ácido nucléico codificando tais variantes, vetores e células hospedeiras compreendendo e expressando o ácido nucléico, composições farmacêuticas, usos e métodos de tratamento. A variante compreende uma substituição em pelo menos uma posição de aminoácido, selecionada do grupo consistindo das posições Lys 157, Lys 337, Asp 334, Ser 336, Val 158, Glu 296 e Met 298.
BR0113854-5A 2000-09-13 2001-09-13 Polipeptìdeo do fator vii, construção de ácido nucleìco, célula hospedeira recombinante animal transgênico, planta transgênica, método para produzir o polipeptìdeo do fator vii, composição farmacêutica, uso de um polipeptìdeo do fator vii, e, métodos para o tratamento de episódios de sangramento e para tratamento ou profilaxia de distúrbios de sangramento em um indivìduo ou para a intensificação do sistema hemostático normal BR0113854A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200001361 2000-09-13
PCT/DK2001/000596 WO2002022776A2 (en) 2000-09-13 2001-09-13 Human coagulation factor vii variants

Publications (1)

Publication Number Publication Date
BR0113854A true BR0113854A (pt) 2004-07-06

Family

ID=8159711

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113854-5A BR0113854A (pt) 2000-09-13 2001-09-13 Polipeptìdeo do fator vii, construção de ácido nucleìco, célula hospedeira recombinante animal transgênico, planta transgênica, método para produzir o polipeptìdeo do fator vii, composição farmacêutica, uso de um polipeptìdeo do fator vii, e, métodos para o tratamento de episódios de sangramento e para tratamento ou profilaxia de distúrbios de sangramento em um indivìduo ou para a intensificação do sistema hemostático normal

Country Status (11)

Country Link
US (3) US7176288B2 (pt)
KR (1) KR100882482B1 (pt)
CN (2) CN100475959C (pt)
BR (1) BR0113854A (pt)
CA (1) CA2420892A1 (pt)
CZ (1) CZ2003611A3 (pt)
ES (1) ES2429523T3 (pt)
MX (1) MXPA03001984A (pt)
NO (1) NO331251B1 (pt)
RU (1) RU2326126C2 (pt)
ZA (1) ZA200301610B (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032690A1 (en) * 1997-09-10 2005-02-10 Rojkjaer Lisa Payne Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia
US7786070B2 (en) 1997-09-10 2010-08-31 Novo Nordisk Healthcare A/G Subcutaneous administration of coagulation factor VII
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
AU783512B2 (en) * 2000-02-11 2005-11-03 Bayer Healthcare Llc Factor VII or VIIa-like molecules
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
AU2002218029A1 (en) * 2000-11-09 2002-05-21 The Scripps Research Institute Modified factor viia
ATE488581T1 (de) * 2002-04-30 2010-12-15 Bayer Healthcare Llc Faktor vii oder faktor viia polypeptidvarianten
CA2502162C (en) * 2002-09-30 2014-04-15 Maxygen Holdings Ltd. Fvii or fviia variants having increased clotting activity
WO2004083361A2 (en) * 2003-03-20 2004-09-30 Maxygen Holdings Ltd. FVII OR FVIIa VARIANTS
MXPA05013769A (es) * 2003-06-19 2006-03-08 Maxygen Holdings Ltd Variantes del dominio gla del factor vii o viia.
WO2005074974A1 (en) * 2004-02-05 2005-08-18 Novo Nordisk Health Care Ag Use of factor viia for treating late complications of trauma
DE602005021509D1 (de) * 2004-08-17 2010-07-08 Csl Behring Gmbh Modifizierte vitamin-k-abhängige polypeptide
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
WO2008009635A2 (en) * 2006-07-17 2008-01-24 Novo Nordisk Health Care Ag Factor viia analogues with increased activity for treating thrombocytopenia
US20100143326A1 (en) * 2007-01-03 2010-06-10 Novo Nordisk Healthcare A/G SUBCUTANEOUS ADMINISTRATION OF COAGULATION FACTOR VIIa-RELATED POLYPEPTIDES
CN103451172A (zh) * 2007-04-13 2013-12-18 催化剂生物科学公司 修饰的因子vii多肽及其应用
EP2014299A1 (en) * 2007-07-11 2009-01-14 Novo Nordisk A/S Subcutaneous administration of coagulation factor VII
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
US20110177580A1 (en) 2008-05-30 2011-07-21 Novo Nordisk Healthcare Ag Method of Controlling a Polypeptide Modification Reaction
CN105727261A (zh) 2008-06-27 2016-07-06 杜克大学 包含弹性蛋白样肽的治疗剂
EP2149603A1 (en) * 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
EP2470559B1 (en) 2009-08-24 2017-03-22 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
EP2633058B1 (en) 2010-10-26 2016-07-20 Hanmi Science Co., Ltd. Method for mass production of factor vii/viia
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
RS63870B1 (sr) 2012-02-15 2023-01-31 Bioverativ Therapeutics Inc Sastavi faktora viii i postupci za pravljenje i upotrebu istih
EP2906693A1 (en) * 2012-10-15 2015-08-19 Novo Nordisk Health Care AG Coagulation factor vii polypeptides
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх
TW202015723A (zh) 2018-05-18 2020-05-01 美商百歐維拉提夫治療公司 治療ａ型血友病的方法
WO2021030787A1 (en) 2019-08-15 2021-02-18 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
DK323587D0 (da) 1987-06-25 1987-06-25 Novo Industri As Protein
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
DE69131292T2 (de) * 1990-01-29 1999-09-30 Zymogenetics, Inc. Antikoagulierende proteine
WO1994007515A1 (en) 1992-10-06 1994-04-14 The Scripps Research Institute Mutant tissue factor lacking factor vii activation activity
CA2162726A1 (en) 1993-05-21 1994-12-08 Kathleen L. Berkner Modified factor vii
WO1997020939A1 (en) 1995-12-01 1997-06-12 Genentech, Inc. TISSUE FACTOR - KUNITZ DOMAIN FUSION PROTEINS AS FACTOR VIIa INHIBITORS
US5736364A (en) 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
JPH1059866A (ja) 1996-08-19 1998-03-03 Chemo Sero Therapeut Res Inst 血液凝固第ｖｉｉ因子及び／もしくは活性化血液凝固第ｖｉｉ因子の製造方法
US6132730A (en) 1997-01-22 2000-10-17 Board Of Regents, The University Of Texas System Combined tissue factor and factor VIIa methods and compositions for coagulation and tumor treatment
WO2001082943A2 (en) 2000-05-03 2001-11-08 Novo Nordisk A/S Subcutaneous administration of coagulation factor vii
US5994296A (en) 1998-03-05 1999-11-30 The Scripps Research Institute Human mutant tissue factor compositions useful as tissue factor antagonists
JP4451514B2 (ja) 1999-08-24 2010-04-14 財団法人化学及血清療法研究所 血液凝固第ｖｉｉ因子改変体
AU783512B2 (en) * 2000-02-11 2005-11-03 Bayer Healthcare Llc Factor VII or VIIa-like molecules
WO2001075086A2 (en) 2000-03-31 2001-10-11 Zymogenetics, Inc. Multi-domain proteinase inhibitor
DE60143292D1 (de) 2000-05-03 2010-12-02 Novo Nordisk Healthcare Ag Varianten des menschlichen Koagulationsfaktors VII
US6905683B2 (en) * 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
DE60112429T2 (de) 2000-05-10 2006-06-01 Novo Nordisk Health Care Ag Verwendung von faktor vii-a und faktor xiii enthaltenden pharmazeutischen verbindungen
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
EP2253703A1 (en) 2000-09-13 2010-11-24 Novo Nordisk Health Care AG Human coagulation factor VII variants
AU2002218029A1 (en) 2000-11-09 2002-05-21 The Scripps Research Institute Modified factor viia
JP2004517950A (ja) 2001-02-05 2004-06-17 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチド及び第ｖｉｉｉ因子ポリペプチドの組合された使用
EP1432794B1 (en) 2001-09-27 2011-11-09 Novo Nordisk Health Care AG Human coagulation factor vii polypeptides
US6960657B2 (en) * 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
EP1546202B1 (en) 2002-09-25 2007-08-22 Novo Nordisk Health Care AG Human coagulation factor vii polypeptides

Also Published As

Publication number Publication date
CZ2003611A3 (cs) 2003-08-13
CN100475959C (zh) 2009-04-08
KR20030067669A (ko) 2003-08-14
US7026524B2 (en) 2006-04-11
NO331251B1 (no) 2011-11-07
ES2429523T3 (es) 2013-11-15
CA2420892A1 (en) 2002-03-21
CN1630721A (zh) 2005-06-22
NO20031129L (no) 2003-05-12
ZA200301610B (en) 2003-09-05
KR100882482B1 (ko) 2009-02-06
RU2326126C2 (ru) 2008-06-10
US20060252129A1 (en) 2006-11-09
MXPA03001984A (es) 2003-08-29
NO20031129D0 (no) 2003-03-12
US7176288B2 (en) 2007-02-13
CN101486761A (zh) 2009-07-22
US20030100740A1 (en) 2003-05-29
US20030104978A1 (en) 2003-06-05
US7695935B2 (en) 2010-04-13

Similar Documents

Publication Publication Date Title
BR0113854A (pt) Polipeptìdeo do fator vii, construção de ácido nucleìco, célula hospedeira recombinante animal transgênico, planta transgênica, método para produzir o polipeptìdeo do fator vii, composição farmacêutica, uso de um polipeptìdeo do fator vii, e, métodos para o tratamento de episódios de sangramento e para tratamento ou profilaxia de distúrbios de sangramento em um indivìduo ou para a intensificação do sistema hemostático normal
BR0212818A (pt) Polipeptìdeo de fator vii, construção de polionucletìdeo, célula hospedeira, animal transgênico, planta transgênica, método para produzir o polipeptìdeo de fator vii composição farmacêutica, uso de um polipeptìdeo de fator vii, e, método para o tratamento de distúrbios do sangramento em um sujeito ou para o aprimoramento do sistema hemostático normal
BR0208203A (pt) Polipeptìdeo do fator vii, derivado do fator vii, composição, composição farmacêutica, construção de polinucleotìdeo, célula hospedeira eucariótica, animal transgênico, planta transgênica, e, métodos para produzir o polipeptìdeo do fator vii e um derivado do fator vii, uso de um derivado do fator vii, métodos para o tratamento de episódios de hemorragia ou distúrbios de hemorragia em um paciente ou para a intensificação do sistema hemostático normal e para inibir a formação de trobo em um paciente
DE60143292D1 (de) Varianten des menschlichen Koagulationsfaktors VII
DE60330923D1 (de) Menschliche Koagulationsfaktor VII Polypeptide
KR960703433A (ko) 증가된 생물학적 활성을 갖는 끝이 잘린 케라틴세포성장인자(kgf) (a truncated keratinocyte growth factor(kgf) having increased biological activity)
WO2003037932A3 (en) Human coagulation factor vii polypeptides
WO2003086451A8 (en) Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
BR0109494A (pt) Produção de fatores recombinantes de coagulação do sangue em linhas celulares humanas
EP2039769A3 (en) Antimicrobial peptides and methods of use
DK0753053T3 (da) Alfavirus-cDNA-vektorer
BRPI0413728A (pt) muteìnas de lipocalina da lágrima
DK0910647T3 (da) Human DNase i hyperaktive varianter
EP0278776A3 (en) Methods and deoxyribonucleic acid for the preparation of tissue factor protein
ATE469217T1 (de) Den phosphorsäure-metabolismus, den kalzium- metabolismus, verkalkung und den vitamin d- metabolismus kontrollierende polypeptide sowie für diese kodierende dna-moleküle
FI850354L (fi) Kompositioner foer anvaendning vid kosmetisk, haelso- och kroppsvaord.
DE60143561D1 (de) Nukleinsäuren kodierend für polypeptide mit chips aktivität
RU2214273C2 (ru) ДНК-ПОСЛЕДОВАТЕЛЬНОСТИ, КОДИРУЮЩИЕ ЧЕЛОВЕЧЕСКИЕ ПРОТЕИНЫ Tx И Ty, РОДСТВЕННЫЕ КОНВЕРГИРУЮЩЕМУ ИНТЕРЛЕЙКИН-1-β ФЕРМЕНТУ
PT83939B (pt) Metodo para a producao de factor angiogenico da placenta humana capaz de estimular a sintese de proteases, sintese de dna e migracao de celulas endoteliais capilares
AR013886A1 (es) Proteinas utiles para tratar la obesidad y condiciones asociadas con la obesidad; composiciones farmaceuticas formuladas con dichas proteinas;compuestos polinucleoticos de dna que codifican dichas proteinas y procedimiento para pepararlas
JP2001213792A5 (pt)
BR0012740A (pt) Compostos para tratamento de distúrbios do sistema infeccioso e imune e métodos para seu emprego
Proost et al. Amino-terminally truncated cc chemokines as chemokine antagonists
KR910016339A (ko) Pp4-델타, 이의 제조방법 및 용도
Suzuki et al. Purification and characterization of chymotrypsin and trypsin from carp (Cyprinus carpio) hepatopancreas

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: NOVO NORDISK HEALTH CARE AG (CH)

Free format text: TRANSFERIDO DE: NOVO NORDISK A/S

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: NOVO NORDISK HEALTH CARE AG (CH)

B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: C12N 9/64

Ipc: C12N 9/64 (2006.01), A61K 38/48 (2006.01), A01H 5/

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2271 DE 15/07/2014.